Elanco Animal Health Incorporated Other Operating Income (Expense), Net
Elanco Animal Health Incorporated (ELAN) reported Other Operating Income (Expense), Net of $6.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherOperatingIncomeExpenseNet · last filed 2026-08-05
- Elanco Animal Health Incorporated other operating income (expense), net for the quarter ending 2026-06-30 was $6.00M.
- Elanco Animal Health Incorporated other operating income (expense), net for the quarter ending 2026-03-31 was -$9.00M.
- Elanco Animal Health Incorporated other operating income (expense), net for the quarter ending 2025-12-31 was $4.00M.
- Elanco Animal Health Incorporated other operating income (expense), net for the quarter ending 2025-09-30 was $0.00.
- Elanco Animal Health Incorporated other operating income (expense), net for fiscal 2025 was -$19.00M.
- Elanco Animal Health Incorporated other operating income (expense), net for fiscal 2024 was -$18.00M.
- Elanco Animal Health Incorporated other operating income (expense), net for fiscal 2023 was -$75.00M.
- Elanco Animal Health Incorporated other operating income (expense), net for fiscal 2022 was -$32.00M.
| Period end | Other Operating Income (Expense), Net 3 month | Other Operating Income (Expense), Net 6 month | Other Operating Income (Expense), Net 9 month | Other Operating Income (Expense), Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.00M 10-Q · filed 2026-08-05 | -$3.00M 10-Q · filed 2026-08-05 | $1.00M derived: sum of 3 quarters · filed 2026-08-05 | $1.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$9.00M 10-Q · filed 2026-05-06 | -$5.00M derived: sum of 2 quarters · filed 2026-05-06 | -$5.00M derived: sum of 3 quarters · filed 2026-05-06 | -$16.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $4.00M derived: sum of 2 quarters · filed 2026-02-24 | -$7.00M derived: sum of 3 quarters · filed 2026-08-05 | -$19.00M 10-K · filed 2026-02-24 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-05 | -$11.00M derived: sum of 2 quarters · filed 2026-08-05 | -$23.00M 10-Q · filed 2025-11-05 | -$29.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$11.00M 10-Q · filed 2026-08-05 | -$23.00M 10-Q · filed 2026-08-05 | -$29.00M derived: sum of 3 quarters · filed 2026-08-05 | -$30.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$12.00M 10-Q · filed 2026-05-06 | -$18.00M derived: sum of 2 quarters · filed 2026-05-06 | -$19.00M derived: sum of 3 quarters · filed 2026-05-06 | -$21.00M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$6.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$7.00M derived: sum of 2 quarters · filed 2026-02-24 | -$9.00M derived: sum of 3 quarters · filed 2026-02-24 | -$18.00M 10-K · filed 2026-02-24 |
| 2024-09-30 | -$1.00M 10-Q · filed 2025-11-05 | -$3.00M derived: sum of 2 quarters · filed 2025-11-05 | -$12.00M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | -$2.00M 10-Q · filed 2025-08-07 | -$11.00M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | -$9.00M 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | -$75.00M 10-K · filed 2026-02-24 | |||
| 2022-12-31 | -$32.00M 10-K · filed 2025-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |